- Analysts reiterated a Buy on Cardlytics Inc (NASDAQ:CDLX) post Q4 results.
- Craig-Hallum analyst Jason Kreyer lowered the firm's price target on Cardlytics from $100 to $70 (15% upside) and kept a Buy.
- The analyst notes quarterly results were strong despite lingering concerns over the supply chain, labor shortages, and omicron issues faced in the quarter.
- That said, management is leaning into the opportunity with direct investments into sales talent, engineering, and retention. The result is further delays in profitability, Kreyer notes.
- Despite an outlook for substantially higher revenue this year, he adds that EBITDA losses will exceed last year to afford these investments.
- Needham analyst Kyle Peterson maintained Cardlytics with a Buy and lowered the price target from $120 to $85 (39% upside).
- Price Action: CDLX shares traded higher by 13.75% at $61.14 on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Analysts Remain Bullish On Cardlytics Post Q4 Results
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks